Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ProLease injectable sustained release formulation of erythropoietin: ALKS partner R.W. Johnson Pharmaceutical Research Institute said it successfully completed

Alkermes Inc. (ALKS), Cambridge, Mass.

Read the full 53 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE